Article Details

Citryll Completes First Closing of a € 15M Series A to Develop its NETosis Inhibiting Antibody

Retrieved on: 2019-07-02 14:00:00

Tags for this article:

Click the tags to see associated articles and topics

Citryll Completes First Closing of a € 15M Series A to Develop its NETosis Inhibiting Antibody. View article details on hiswai:

Excerpt

<div>BrightGene INTERNATIONAL (Hong Kong) LIMITED is a wholly-owned subsidiary of BrightGene Bio-medical technology Co.,Ltd.,<b>Sequoia Capital</b> ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up